Meningococcal Vaccine

Réussis tes devoirs et examens dès maintenant avec Quizwiz!

A, B, C, Y, W

Most invasive disease caused by serogroups ____________.

3 doses at 0, 1-2 months, and 6 months

Trumenba dosing: ___________

thimerosal

10-dose vial contains ________ as a preservative. (MPSV)

MPSV

Approved for 2 and older but not currently recommended for routine vaccination to younger patients.

13

At least ________ serogroups based on characteristics of polysaccharide capsule

2 doses given 1 month apart

Bexsero dosing: ________________

MENACWY and MPSV4

Both ________________ recommended for control outbreaks caused by vaccine-preventable serogroups (Men B only for outbreaks of serogroup B).

- Fever - Headache - Stiff neck

Clinical features of meningococcal meningitis: _____________

- Abrupt onset of fever - Meningeal symptoms (stiff neck, headache, photophobia) - Hypotension - Rash

Clinical symptoms include: ___________

- Quadrivalent meningococcal conjugate vaccine - Meningococcal polysaccharide vaccine - Serogroup B vaccine

Different types of vaccines include: _______________

rapidly, morbidity and mortality

Disease develops _______ and has high _____________.

MenB vaccine

Examples include: - Bexsero - Trumenba

10-15%

Fatality rate __________

Meningococcal serogroup B

Incidence is stable and low in adolescents and young adults; ~50-60 cases and 5-10 deaths reported annually.

- Infants and children 5 and younger - Young adults 16-21 - Adults 65 and older

Incidence of neisseria meningitides peaks in 3 age groups: ____________

3-4 days (range 2-10 days)

Incubation period _______.

Quadrivalent meningococcal conjugate vaccine

MENACWY

11-12 years (booster dose at 16), 13-15 (booster dose at 16-18)

MENACWY recommendations: administer at _________________. Catch up dose at _________ if not previously vaccinated.

administer 1 dose with no booster

MENACWY recommendations: if patients is > 16 years, _________________ (catch up)

2 dose series 8 weeks apart

MENACWY recommended for PCCD* or asplenic patients: ______________.

21

MENACWY routine vaccination NOT recommended after __________ for healthy persons not at increased risk of exposure.

Meningococcal polysaccharide vaccine

MPSV

3rd generation cephalosporin or vancomycin

Medical management includes initial emperic antibiotic therapy with ______________________ after appropriate cultures are obtained.

Sub-Saharan africa

Meningitis an epidemic disease in _____________

< 2%

Meningococcal outbreaks account for ______ of reported cases.

blood stream infection

Meningococcemia is a _____________.

Meningococcal meningitis

Most common pathological presentation; results of hematogenous dissemination.

meningitis, sepsis, focal infections (pneumonia and arthritis)

Neisseria Meningitidis causes ______________

- 3 or more confirmed or probable primary cases - Period <3 months - Primary attack rate > 10 cases per 100,000 population

Outbreak definition: ________________

Meningococcal polysaccharide vaccine

Quadrivalent polysaccharide vaccine administered by SubQ injection.

geographic location and other factors (age)

Relative importance of serogroups depends on ___________.

Neisseria Meningitidis

Severe acute gram - bacterial infection

MPSV

Should only be used for persons at increased risk of N. Meningitidis infection who are 56 and older or if MCV4 is not available.

penicillin alone

Treatment with _______________ after confirmation of N. Mengitidis.

11-19%

_______ of survivors have long term sequelae including deafness, limb or digit loss, and neurologic disability.

MPSV

_________ is no longer commonly used.

Chemoprophylaxis

________________ for close contacts of infected persons during 7 days before symptom onset.


Ensembles d'études connexes

Taxation of Non Qualified Annuities

View Set

Scale Drawings - Perimeter and Area

View Set

Accounting 210 Midterm 2 Interterm

View Set

Biology Unit 1 - Scientific Method

View Set